XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2011
Jun. 30, 2016
Dec. 31, 2014
Mar. 31, 2014
Dec. 31, 2012
Sep. 30, 2016
Feb. 29, 2016
Dec. 31, 2015
Aug. 31, 2014
May 31, 2012
Aug. 31, 2010
Deferred Revenue Arrangement [Line Items]                      
Accrued research and development liability           $ 4,702,000   $ 7,361,000      
Accrued current liabilities           21,988,000   15,337,000      
Maximum                      
Deferred Revenue Arrangement [Line Items]                      
Additional revenue recognized           100,000,000          
Astra Zeneca                      
Deferred Revenue Arrangement [Line Items]                      
Collaboration Revenue $ 3,000,000   $ 8,000,000 $ 5,400,000 $ 6,000,000            
Accrued current liabilities           7,400,000          
Additional collaboration revenue   $ 800,000                  
Deferred revenue           $ 0   $ 2,700,000      
National Institutes of Health                      
Deferred Revenue Arrangement [Line Items]                      
Grants receivable                 $ 200,000    
National Institutes of Health | Rheumatoid Arthritis                      
Deferred Revenue Arrangement [Line Items]                      
Grants receivable             $ 500,000     $ 400,000  
National Institute of Allergy and Infectious Diseases | Hepatitis B Virus                      
Deferred Revenue Arrangement [Line Items]                      
Grants receivable                     $ 1,400,000